Bioventus launched its DUROLANE® single-injection hyaluronic acid-based osteoarthritis (OA) treatment in Taiwan, to be marketed by Eulogiums for mild to moderate knee OA.
Bioventus’ orthobiologic products are now available in six countries in the Asia Pacific region.
In 1Q14, Bioventus acquired ex-U.S. DUROLANE assets from Galderma, which still manufactures the product.
Bioventus launched its DUROLANE® single-injection hyaluronic acid-based osteoarthritis (OA) treatment in Taiwan, to be marketed by Eulogiums for mild to moderate knee OA.
Bioventus' orthobiologic products are now available in six countries in the Asia Pacific region.
Source:...
Bioventus launched its DUROLANE® single-injection hyaluronic acid-based osteoarthritis (OA) treatment in Taiwan, to be marketed by Eulogiums for mild to moderate knee OA.
Bioventus’ orthobiologic products are now available in six countries in the Asia Pacific region.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
